A Post Authorisation Registry of IMNOVID (Pomalidomide) for Patients With Relapsed and Refractory Multiple Myeloma.

NCT ID: NCT02164955

Last Updated: 2022-10-20

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

775 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-06-26

Study Completion Date

2022-10-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This registry is a prospective, multi-center, observational study and will collect safety data on multiple myeloma adult patients who have received at least two prior therapies and take IMNOVID (pomalidomide) as part of standard care.

The registry will remain open until 500 patients will have received at least 3 cycles of pomalidomide. All patients registered will be followed for up to 3 years after the informed consent date or until death or withdrawal of consent. During this time the incidence of second primary malignancies (SPM), overall survival and any occurrence of a pregnancy will be assessed.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Multiple Myeloma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Relapsed and Refractory Multiple Myeloma Patients

Single Cohort of Relapsed and Refractory Multiple Myeloma Patients treated with IMNOVID (pomalidomide)

IMNOVID

Intervention Type DRUG

IMNOVID (pomalidomide) as prescribed in routine clinical practice

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

IMNOVID

IMNOVID (pomalidomide) as prescribed in routine clinical practice

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

pomalidomide CC-4047 BMS-986379

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Understand and voluntarily sign an informed consent form, if applicable, and have never been previously treated with pomalidomide before their inclusion in the Registry.

Patients with symptomatic, measurable relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both bortezomib and lenalidomide and have demonstrated disease progression on the last therapy and are commencing a pomalidomide based treatment.

Exclusion Criteria

Refusal to participate in the Registry or currently participating in the treatment phase of an interventional clinical trial.

Pregnancy.

Women of childbearing potential, unless all the conditions of the pregnancy prevention program are met.

Male patients unable to follow or comply with the required contraceptive measures.

Hypersensitivity to the active substance or to any of the excipients.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Celgene

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Bristol-Myers Squibb

Role: STUDY_DIRECTOR

Bristol-Myers Squibb

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Cliniques Universitaires Saint Luc

Brussels, Avenue Hippocrate 10, Belgium

Site Status

Ziekenhuis Netwerk Antwerpen- Campus Middelheim

Antwerp, Lindendreef 1, Belgium

Site Status

Az Nikolaas

Sint-Niklaas, Lodewijk de Meesterstraat 5, Belgium

Site Status

Centre Hospitalier Peltzer-La Tourelle

Verviers, Rue Du Parc 29, Belgium

Site Status

Centre hospitalier de Jolimont

La Louvière, Rue Ferrer 159, Belgium

Site Status

Les Cliniques Du Sud Luxembourg- Clinique Saint-Joseph

Arlon, , Belgium

Site Status

Universitair Ziekenhuis Antwerpen

Edegem, , Belgium

Site Status

CHC

Liège, , Belgium

Site Status

Clinique Saint-Pierre

Ottignies, , Belgium

Site Status

Odense Hospital

Odense, Kloevervanget 10, Denmark

Site Status

Aarhus Universitetshospital

Karup, Noerrebrogade 44, Denmark

Site Status

Vejle Hospital, Dep of hema Kabbeltoft, Kabbeltoft 25

Vejle, , Denmark

Site Status

Gemeinschaftspraxis Fur Hamatologie Und Onkologie

Koln-Kalk, Buchforststr 14, Germany

Site Status

Charite der Humboldt-Universität

Berlin, Chariteplatz 1, Germany

Site Status

Klinikum Enroll von Bergmann

Potsdam, Charlotteustr 72, Germany

Site Status

Klinikum Traunstein

Traunstein, Cuno-Niggl-Strate 3, Germany

Site Status

Studienzentrum Haematologie/Onkologie/Diabetologie

Aschaffenburg, Elisenstr.26, Germany

Site Status

Universitaetsklinikum Essen, Westdeutsches Tumorzentrum

Essen, Hufelandstraße 55, Germany

Site Status

Diakonie-Klinikum Schwabisch Hall

Schwäbisch Hall, Innere Medizin III, Germany

Site Status

UBAG MVZ Mitte/ MVZ Delitzsch GmbH

Delitzsch, Ludwig- Jahn- Str. 4, Germany

Site Status

Klinikum Grosshadern-Klinikum Der Ludwig-Maximilian Universitaet Muenchen

München, Marchioninistr. 15, Germany

Site Status

Stadtisches Klinikum Karlsruhe

Karlsruhe, Medizinische Klinik III, Germany

Site Status

Schwerpunktpraxis und Tagesklinik fur Hamatologie und Onkologie

Kronach, Niederbronner Stabe 2, Germany

Site Status

Klinikum Lippe-Lemgo

Minden, Rintelner Strae 85, Germany

Site Status

HELIOS Klinikum Berlin-Buch

Berlin, Schwanebecker Chaussee 50, Germany

Site Status

Malteser Krankenhaus St. Franziskus Hospital

Flensburg, Waldstr. 17, Germany

Site Status

Dr. Reiner Weinberg, Md, Office Of

Aachen, Weberstr. 8, Germany

Site Status

Evangelisches Krankenhaus Hamm GgmbH

Hamm, Werler Str. 110, Germany

Site Status

Carl-Thiem-Klinikum Cottbus

Cottbus, , Germany

Site Status

Klinikum Frankfurt Höchst, Klinik für Innere Medizin 3

Frankfurt, , Germany

Site Status

GP Dres. Verpoort

Hamburg, , Germany

Site Status

Uberortliche Gemeinschaftspraxis - Schwerpunkt Haematologie, internistische Onkologie & Palliativmedizin, Dres. Verpoort, Wierecky & Zeller

Hamburg, , Germany

Site Status

Praxis Dr Schwarzer

Leipzig, , Germany

Site Status

Johannes Wesling Klinikum Minden

Minden, , Germany

Site Status

Klinik für Hämatologie, Onkologie und Palliativmedizin Mühlenkreiskliniken, Johannes Wesling Klinikum Minden

Minden, , Germany

Site Status

Gemeinschaftspraxis für, Hämato-Onkologie am St. Josef, Krankenhaus Moers

Moers, , Germany

Site Status

Stauferklinikum Schwaebisch Gmuend

Mutlangen, , Germany

Site Status

Zentrum für Innere Medizin

Mutlangen, , Germany

Site Status

Studienzentrum Onkologie Ravensburg

Ravensburg, , Germany

Site Status

Laboratorio Analisi Ospedale Casa Sollievo della Sofferenza

San Giovanni Rotondo, FG, Italy

Site Status

AOUC Azienda Ospedaliero-Universitaria Careggi

Florence, Florence, Italy

Site Status

Reparto Di Ematologia Dell'Azienda

Brescia, Lombardy, Italy

Site Status

Azienda Ospedaliera Di Rilievo Nazionale (AORN) 'Antonio Cardarelli'

Napoli, Naples, Italy

Site Status

Institute of Hematology- Sapienza University -Rome, Italy

Roma, Rome, Italy

Site Status

Azienda Ospedaliera Universitaria di Padova

Padua, Veneto, Italy

Site Status

Azienda Ospedaliera Univarsitaria Consorziale Policlinico di Bari

Bari, , Italy

Site Status

Azienda Ospedaliera Ospedali Riuniti di Bergamo

Bergamo, , Italy

Site Status

AOU-S.Orsola-Malpighi - Universita degli Studi di Bologna

Bologna, , Italy

Site Status

Azienda Ospedaliera Spedali Civili di Brescia-Universita degli Studi Di Brescia

Brescia, , Italy

Site Status

Centro Trapianti Midollo Osseo Ospedale Bnaghi

Cagliari, , Italy

Site Status

A.O.U. Vittorio Emanuele di Catania-Ospedale Ferrarotto

Catania, , Italy

Site Status

Azienda Ospedaliera Universitaria "San Martino"

Genova, , Italy

Site Status

Ospedale San Raffaele Srl

Milan, , Italy

Site Status

Ematologia, Policlinico di Milano

Milan, , Italy

Site Status

Casa di Cura La Maddalena

Palermo, , Italy

Site Status

AOUP, Santa Chiara Hospital

Pisa, , Italy

Site Status

A.O. Bianchi Melacrino Morelli

Reggio Calabria, , Italy

Site Status

Arcispedale S. Maria Nuova

Reggio Emilia, , Italy

Site Status

Policlinico S.Eugenio

Roma, , Italy

Site Status

A.O.U.S. Giovanni e Ruggi d'Aragona UOC UTIC

Salerno, , Italy

Site Status

AOU Ospedali Riuniti Umbertio I

Torrette Di Ancona, , Italy

Site Status

U.O Ematologia Az. ULSS9 di Treviso

Treviso, , Italy

Site Status

Unita di Oncologia Polmonare A.o. San

Turin, , Italy

Site Status

Universita Degli Studi Policlinico

Udine, , Italy

Site Status

HF Alesund Hospital

Ålesund, , Norway

Site Status

Helse Bergen HF Haukeland University Hospital

Bergen, , Norway

Site Status

Vestre Viken/Baerums sjukhus

Drammen, , Norway

Site Status

Fredrikstad Hospital

Fredrikstad, , Norway

Site Status

Hospital Costa Del Sol

Marbella, Autovia A-7, Km 187, Spain

Site Status

University Hospital Reina Sofia

Córdoba, Avda Menendez Pidal S/n, Spain

Site Status

Nuestra Senora de Valme

Seville, Avda. Bellavista, S/N, Spain

Site Status

Hospital Puerta del Mar

Cadiz, Avenida Ana de Viya, 21, Spain

Site Status

Hospital Universitario Central de Asturias

Oviedo, Avenida de Roma S/n, Spain

Site Status

General de Jane

Jaén, Avenida Ejercito Espanol 10, Spain

Site Status

General San Pedro de Alcantara

Cáceres, Avenida Pablo Naranjo Porras, Spain

Site Status

Hospital Clinico Universitario De Valladolid

Valladolid, Avenida Ramon Y Cajal 3, Spain

Site Status

Hospital Universitario de La Princesa

Madrid, C/ Diego de León 62, 3a Planta, Spain

Site Status

Hospital Xeral de Lugo

Lugo, C/ Doctor Severo Ochoa S/N, Spain

Site Status

Hospital Son Dureta

Palma de Mallorca, Calle Andrea Doria 55, Spain

Site Status

Hospital General Universitario Santa Lucia

Cartagena (murcia), Calle Mezquita, Spain

Site Status

Hospital Arnau De Vilanova De Valencia

Valencia, Calle San Clemente, 12, Spain

Site Status

Hospital General Universitario de Elche

Elche, CAMI de L´almassera 11, Spain

Site Status

Hospital de Cabuenes

Gijón, Camino de Los Prados, Spain

Site Status

Hospital Universitario Nuestra Senora De Candelaria

Santa Cruz de Tenerife, Carretera Del Rosario, 145, Spain

Site Status

Hospital Fundacion Son Llatzer

Palma de Mallorca, Ctra. Manacor, Km. 4, Spain

Site Status

Hospital universitario de Alava

Alava, Jose Achotegui, Spain

Site Status

IC0 Duran y Reynalds

Barcelona, L´Hospitalet de Llobregat, Spain

Site Status

Hospital Universitari Vall d'Hebron

Barcelona, Passeig de La Vall D'Hebron 119-129, Spain

Site Status

Ctra. Orihuela - Almoradi

Orihuela (alicante), S/N San Bartolome, Spain

Site Status

Hospital Universitario Virgen de la Victoria

Málaga, Servicio de Oncologia, Spain

Site Status

Sunderby Hospital

Luleå, , Sweden

Site Status

University Hospital UMEA

Umeå, , Sweden

Site Status

Pinderfields Hospital-Mid Yorkshire Nhs Trust

Wakefield, Aberford Road, United Kingdom

Site Status

Doncaster Royal Infirmary - Doncaster And Bassetlaw Hospitals Nhs Foundation Trust

Doncaster, Armthorpe Road, United Kingdom

Site Status

Northhampton Gerneral Hospital

Northampton, Cliftonville, United Kingdom

Site Status

County Durham and Darlington NHS foundation Trust

County Durham, Darlington Memorial Hospital, United Kingdom

Site Status

Broomfield Hospital

Broomfield,Chelmsford, Essex, United Kingdom

Site Status

Aberdeen Royal Infirmary - Nhs Grampian

Aberdeen, Foresterhill Road, United Kingdom

Site Status

The Newcastle Upon Tyne Hospitals Nhs Foundation

Newcastle upon Tyne, Freeman Hospital, United Kingdom

Site Status

Lincoln County Hospital - United Lincolnshire Hospitals Nhs Trust

Lincoln, Greetwell Road, United Kingdom

Site Status

Maidstone Hospital - Maidstone And Tunbridge Wells Nhs Trust-Kent Oncology Centre

Maidstone, Kent, United Kingdom

Site Status

Blackpool Victoria Hospital - Blackpool, Fylde And Wyre Hospitals Nhs Foundation Trust

Blackpool, Lancashire, United Kingdom

Site Status

Huddersfield Royal Infirmary - Calderdale And Huddersfield Nhs Foundation Trust

Huddersfield, Lindley, United Kingdom

Site Status

Worthing Hospital - Western Sussex Hospitals Nhs Trust

Worthing, Lyndhurst Road, United Kingdom

Site Status

Monklands Hospital Trust: Nhs Lanarkshire - Acute Services Division

Airdrie, Monkscourt Avenue, United Kingdom

Site Status

Southmead Hospital - North Bristol Nhs Trust Recruiting

Bristol, Southmead Road, United Kingdom

Site Status

City Hospitals Sunderland NHS Trust Recruiting

Sunderland, Sunderland Royal Hospital, United Kingdom

Site Status

Colchester General Hospital - Colchester Hospital University Nhs Foundation Trust

Colchester, Turner Road, United Kingdom

Site Status

University Hospital of Wales

Cardiff, Vale Of Glamorgan, United Kingdom

Site Status

Northwick Park Hospital - North West London Hospitals Nhs Trust

Harrow, Watford Road, United Kingdom

Site Status

Singleton Hospital - Abertawe Bro Morgannwg University Nhs Trust

Swansea, West Glamorgan, United Kingdom

Site Status

Worcestershire Acute Hospitals NHS Trust - Worcestershire Royal Hospital

Worcester, Worcestershire, United Kingdom

Site Status

St Helier Hospital - Epsom and St Helier University Hospitals NHS Trust

Carshalton, Wrythe Lane, United Kingdom

Site Status

Basingstoke and North Hampshire Hospital

Basingstoke, , United Kingdom

Site Status

Royal United Hospital, Bath - Royal United Hospital Bath NHS Trust

Bath, , United Kingdom

Site Status

Dorset County Hospital

Dorchester, , United Kingdom

Site Status

The Royal Liverpool and Broadgreen -University Hospitals NHS

Liverpool, , United Kingdom

Site Status

Specialist Cancer Pharmacist-Oxford Cancer Centre & Cancer Research UK-Churchill Hospital-Oxford University Hospitals NHS Trust

Oxford, , United Kingdom

Site Status

Royal Berkshire hospital

Reading, , United Kingdom

Site Status

Wexham Park Hospital

Slough, , United Kingdom

Site Status

Royal Cornwall Hospital

Truro, , United Kingdom

Site Status

Northumbria Healthcare NHS Foundation Trust North Tyneside Hospital

Tyne and Wear, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Belgium Denmark Germany Italy Norway Spain Sweden United Kingdom

References

Explore related publications, articles, or registry entries linked to this study.

Moreau P, Dimopoulos MA, Richardson PG, Siegel DS, Cavo M, Corradini P, Weisel K, Delforge M, O'Gorman P, Song K, Chen C, Bahlis N, Oriol A, Hansson M, Kaiser M, Anttila P, Raymakers R, Joao C, Cook G, Sternas L, Biyukov T, Slaughter A, Hong K, Herring J, Yu X, Zaki M, San-Miguel J. Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis. Eur J Haematol. 2017 Sep;99(3):199-206. doi: 10.1111/ejh.12903. Epub 2017 Jun 14.

Reference Type BACKGROUND
PMID: 28504846 (View on PubMed)

Schafer PH, Ye Y, Wu L, Kosek J, Ringheim G, Yang Z, Liu L, Thomas M, Palmisano M, Chopra R. Cereblon modulator iberdomide induces degradation of the transcription factors Ikaros and Aiolos: immunomodulation in healthy volunteers and relevance to systemic lupus erythematosus. Ann Rheum Dis. 2018 Oct;77(10):1516-1523. doi: 10.1136/annrheumdis-2017-212916. Epub 2018 Jun 26.

Reference Type BACKGROUND
PMID: 29945920 (View on PubMed)

Dinner S, Dunn TJ, Price E, Coutre SE, Gotlib J, Berube C, Kaufman GP, Medeiros BC, Liedtke M. A phase I, open-label, dose-escalation study of amrubicin in combination with lenalidomide and weekly dexamethasone in previously treated adults with relapsed or refractory multiple myeloma. Int J Hematol. 2018 Sep;108(3):267-273. doi: 10.1007/s12185-018-2468-5. Epub 2018 May 25.

Reference Type BACKGROUND
PMID: 29802551 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CC-4047-MM-015

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.